{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:46:40Z","timestamp":1784288800425,"version":"3.55.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972690"],"award-info":[{"award-number":["81972690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81000914"],"award-info":[{"award-number":["81000914"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognosis of patients with metastatic malignant melanoma is very poor and partly due to resistance to conventional chemotherapies. The study\u2019s objectives were to assess the activity and tolerability of apatinib, an oral small molecule anti-angiogenesis inhibitor, in patients with recurrent advanced melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-arm, single-center phase II trial. The primary endpoint was progression-free survival (PFS) and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Eligible patients had received at least one first-line therapy for advanced melanoma and experienced recurrence. Apatinib (500\u00a0mg) was orally administered daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen patients (V660E BRAF status: 2 mutation, 2 unknown, 11 wild type) were included in the analysis. The median PFS was 4.0 months. There were two major objective responses, for a 13.3% response rate. Eleven patients had stable disease, with a DCR of 86.7%. The median OS was 12.0 months. The most common treatment-related adverse events of any grade were hypertension (80.0%), mucositis oral (33.3%), hand-foot skin reaction (26.7%), and liver function abnormalities, hemorrhage, diarrhea (each 20%). The only grade \u22653 treatment-related adverse effects that occurred in 2 patients was hypertension (6.7%) and mucositis (6.7%). No treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Apatinib showed antitumor activity as a second- or above-line therapy in patients with malignant melanoma. The toxicity was manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                    <jats:p>NCT03383237<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyab068","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T15:09:44Z","timestamp":1641308984000},"page":"e463-e470","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma"],"prefix":"10.1093","volume":"27","author":[{"given":"Shumin","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingdi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiepeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingkun","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingke","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaomin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanli","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"2022060819201257100_CIT0001","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.tranon.2018.07.009","article-title":"Safety and efficacy of apatinib combined with temozolomide in advanced melanoma patients after conventional treatment failure.","volume":"11","author":"Yang","year":"2018","journal-title":"Transl Oncol"},{"key":"2022060819201257100_CIT0002","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.2147\/OTT.S175507","article-title":"Apatinib mesylate tablet in the treatment of advanced malignant melanoma.","volume":"11","author":"Yang","year":"2018","journal-title":"Onco Targets Ther."},{"issue":"21","key":"2022060819201257100_CIT0003","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma.","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer."},{"issue":"6","key":"2022060819201257100_CIT0004","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo."},{"issue":"8","key":"2022060819201257100_CIT0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"issue":"9839","key":"2022060819201257100_CIT0006","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet."},{"issue":"3","key":"2022060819201257100_CIT0007","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"issue":"4","key":"2022060819201257100_CIT0008","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"2022060819201257100_CIT0009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"issue":"9992","key":"2022060819201257100_CIT0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(15)60972-2","article-title":"Inhibition of BRAF and MEK in BRAF-mutant melanoma.","volume":"386","author":"Smalley","year":"2015","journal-title":"Lancet."},{"issue":"8","key":"2022060819201257100_CIT0011","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"2022060819201257100_CIT0012","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"issue":"9","key":"2022060819201257100_CIT0013","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"2022060819201257100_CIT0014","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"issue":"9992","key":"2022060819201257100_CIT0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.","volume":"386","author":"Long","year":"2015","journal-title":"Lancet."},{"issue":"10","key":"2022060819201257100_CIT0016","doi-asserted-by":"crossref","first-page":"e0139438","DOI":"10.1371\/journal.pone.0139438","article-title":"Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival?","volume":"10","author":"Mangana","year":"2015","journal-title":"PLoS One."},{"issue":"26","key":"2022060819201257100_CIT0017","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"issue":"5","key":"2022060819201257100_CIT0018","doi-asserted-by":"crossref","first-page":"740","DOI":"10.21147\/j.issn.1000-9604.2019.05.03","article-title":"Comments on Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version).","volume":"31","author":"Bai","year":"2019","journal-title":"Chin J Cancer Res"},{"issue":"4","key":"2022060819201257100_CIT0019","doi-asserted-by":"crossref","first-page":"578","DOI":"10.21147\/j.issn.1000-9604.2019.04.02","article-title":"Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version).","volume":"31","author":"No authors listed","year":"2019","journal-title":"Chin J Cancer Res"},{"issue":"7","key":"2022060819201257100_CIT0020","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma.","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"issue":"1","key":"2022060819201257100_CIT0021","doi-asserted-by":"crossref","first-page":"e000341","DOI":"10.1136\/jitc-2019-000341","article-title":"Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.","volume":"8","author":"Klemen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2022060819201257100_CIT0022","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci."},{"issue":"5","key":"2022060819201257100_CIT0023","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bcp.2011.12.007","article-title":"Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells.","volume":"83","author":"Tong","year":"2012","journal-title":"Biochem Pharmacol."},{"issue":"1","key":"2022060819201257100_CIT0024","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/14656566.2015.981526","article-title":"Apatinib for the treatment of gastric cancer.","volume":"16","author":"Geng","year":"2015","journal-title":"Expert Opin Pharmacother."},{"issue":"9","key":"2022060819201257100_CIT0025","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1002\/cam4.1664","article-title":"Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.","volume":"7","author":"Yang","year":"2018","journal-title":"Cancer Med."},{"issue":"1","key":"2022060819201257100_CIT0026","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12879-018-3413-1","article-title":"Preoperative oral antibiotic prophylaxis reduces Pseudomonas aeruginosa surgical site infections after elective colorectal surgery: a multicenter prospective cohort study.","volume":"18","author":"Gomila","year":"2018","journal-title":"BMC Infect Dis."},{"issue":"13","key":"2022060819201257100_CIT0027","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol."},{"issue":"49","key":"2022060819201257100_CIT0028","doi-asserted-by":"crossref","first-page":"e9053","DOI":"10.1097\/MD.0000000000009053","article-title":"A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial\/Experimental Study.","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)."},{"issue":"26","key":"2022060819201257100_CIT0029","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"issue":"2","key":"2022060819201257100_CIT0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma.","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med."},{"issue":"3","key":"2022060819201257100_CIT0031","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol."},{"issue":"7","key":"2022060819201257100_CIT0032","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma.","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med."},{"issue":"10","key":"2022060819201257100_CIT0033","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"9","key":"2022060819201257100_CIT0034","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"2022060819201257100_CIT0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer."},{"key":"2022060819201257100_CIT0036","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy289.039","article-title":"Treatment pattern and clinical outcomes of patients with locally advanced and metastatic melanoma in a real-world setting in China.","volume":"29","author":"Cui","year":"2018","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/6\/e463\/43984320\/oyab068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/6\/e463\/43984320\/oyab068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T15:20:50Z","timestamp":1654701650000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/6\/e463\/6555073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2022,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyab068","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-67706\/v1","asserted-by":"object"}]},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,28]]}}}